Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Settles Sales Rep Overtime Suit Rather Than Await Supreme Court Ruling

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis agrees to pay $99 million to resolve a class action on behalf of 7,700 current and former sales representatives. The company changed the duties of its reps and cut their work hours after the suit was filed.

Advertisement

Related Content

Supreme Court’s Pro-Pharma Decision On Sales Rep Overtime Reproves Informal Agency Policymaking
Sales Reps Overtime Suit Goes To Supreme Court; Could The IMS Win Bite Pharma?
For Novartis, 2012 Is Set To Be A Bumpy Ride
Is A Pharma Sales Rep A Salesman? Supreme Court To Make Final Call
Novartis Will Track Gender Disparities In Performance Evaluations Under Settlement
Pharma Sales Reps May Get Overtime After Appeals Court Defers To Department Of Labor
Sales Rep Suits Seek Overtime Pay; Off-Label Promotion May Get Its Day In Court

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel